PatientsVille.com Logo


Mirapexin Medical Research Studies

Up-to-date List of Mirapexin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Mirapexin Medical Research Studies

Rank Status Study
1 Recruiting Pramipexole as a Treatment for Cocaine Dependence
Conditions: Cocaine Addiction;   Cocaine Abuse;   Cocaine Dependence;   Substance Abuse
Interventions: Drug: Pramipexole;   Drug: Placebo
Outcome Measures: The effects of pramipexole and cocaine on cardiovascular measures;   The effects of pramipexole and cocaine on subjective measures
2 Unknown  Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
Condition: Essential Tremor
Interventions: Drug: pramipexole;   Drug: placebo
Outcome Measures: Improvement in tremor severity;   Improvement in quality of life;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability
3 Unknown  Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)
Condition: Parkinson's Disease
Intervention: Drug: Mirapex ER
Outcome Measures: Patient preference;   Motor complications;   Sleep problems;   Motor UPDRS and HY stage;   Side effects;   Patient global impression for improvement;   Preference in each factor;   Patient choice
4 Recruiting Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Dexpramipexole;   Drug: Corticosteroid Taper
Outcome Measures: A binary response indicating whether or not the subject had a greater than or equal to 50 % change in prednisone dose to maintain AEC & lt; 1000/microL and control clinical symptoms and 2) the change in minimal effective corticosteroid dose...;   Reduction in circulating eosinophils after 3 months of treatment with dexpramipexole (prior to steroid taper);   Reduction in bone marrow eosinophils and myeloid precursors after 3 months of treatment with dexpramipexole (prior to steroid taper);   Number of subjects able to taper to & lt; 10 mg prednisone and maintain AEC& lt; 1000/microL and control of clinical symptoms;   Incidence and severity of adverse events
5 Recruiting Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: pramipexole;   Drug: Bromocriptine
Outcome Measures: K-NMSS;   K-MADRS;   UPDRS I/II/III;   K-PDQ39
6 Unknown  Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: minocycline;   Drug: pramipexole;   Drug: acetylsalicylic acid;   Drug: placebo
Outcome Measures: Positive and Negative Syndrome Scale (PANSS)total score;   Positive and Negative Syndrome Scale (PANSS);   Clinical Global Impression Scale-Severity (CGI-S);   Clinical Global Impression Scale-Severity(CGI-S);   Clinical Global Impression Scale- Improvement (CGI-I);   Brief Assessment of Cognition in Schizophrenia (BACS)
7 Recruiting Imaging Dopamine Release in Depression
Condition: Major Depressive Disorder
Intervention: Drug: Pramipexole
Outcome Measures: Change in Hamilton Rating Scale for Depression;   Change in Snaith Hamilton Pleasure Scale;   Change in Temporal Experience of Pleasure Scale;   Change in Mood and Anxiety Symptom Questionnaire, Short Form;   Change in the Apathy Evaluation Rating Scale;   Change in Items on Side Effect Checklist;   Change in Columbia Suicide Severity Rating Scale;   Clinical Global Improvement - Change Scale
8 Recruiting Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
Condition: Restless Legs Syndrome
Interventions: Drug: Pramipexole;   Drug: Placebo
Outcome Measures: Change in heart rate activations during sleep from baseline to 4 weeks;   Change in baroreflex from baseline to 4 weeks;   Change in blood serum markers from baseline to 4 weeks
9 Recruiting Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological and Pharmacokinetic Profiles
Conditions: Parkinson's Disease;   Secondary Behavioural Addiction
Intervention: Other: questionnaires
Outcome Measures: Psychopathological axis : score of sensation seeking (S Score) of the impulsivity questionnaire "UPPS";   Pharmacological axis : Area under the curve of the pramipexole concentration;   Neurological axis : Unified Parkinson's Disease Rating Scale (UPDRS) III score;   Treatments except the anti-parkinsonism ones;   drug misuse;   addiction and punding antecedents;   ADHD antecedents;   impulsivity profile;   Age of onset of the Parkinson's disease;   stage and form of the Parkinson's disease;   time course of Parkinson's disease;   family history of Parkinson's disease;   anti-parkinsonism treatments;   Residual plasmatic concentration of the pramipexole;   median pharmacokinetic parameters of pramipexole;   study of the hepatic and renal functions;   Physiopathological covariates
10 Recruiting Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: Pramipexole / Rasagiline Mesylate once daily;   Drug: Placebo
Outcome Measures: Total UPDRS I, II, III scores;   UPDRS ADL (part II);   CGI-S;   UPDRS Motor (part III);   PDQ39
11 Not yet recruiting Butrans for Treatment of Restless Legs Syndrome
Condition: Restless Legs Syndrome
Interventions: Drug: buprenorphine transdermal delivery system (BTDS);   Drug: Placebo for BTDS patch
Outcome Measures: The International Restless Legs Scale (IRLS);   Clinical Global Impression of Improvement
12 Unknown  Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Ropinirole Hydrochloride
Outcome Measure:
13 Not yet recruiting Switching From Oral Dopamine Agonists to Rotigotine
Conditions: Restless Legs Syndrome;   Ekbom Syndrome;   Willis-Ekbom Disease
Intervention: Drug: Rotigotine
Outcome Measures: Proportion of patients completing the switch and their adverse events;   International Restless Legs Scale (IRLS);   RLS-6 Scales;   Preference of Medication Scale (POM);   The Patient Global Impression of Change scale;   The Clinician Global Impression of Change Scale

These studies may lead to new treatments and are adding insight into Mirapexin etiology and treatment.

A major focus of Mirapexin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Mirapexin